Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1005 in Overweight or Obese Subjects
NCT06637020Phase 1Completed
- Sponsor
- Huadong Medicine
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of poterepatide in obesity (5 arms), sponsored by Huadong Medicine. Primary endpoint: Incidence, severity, and causality of treatment-emergent adverse events and serious adverse events at Day 57. Started Jun 2024; status: completed.
02
Drugs
poterepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06637020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637020.